Itacitinib (Synonyms: INCB 039110) |
| Katalog-Nr.GC19204 |
Itacitinib (INCB039110) ist ein oral aktiver und selektiver Inhibitor von JAK1 mit einer IC50 von 2 nM fÜr humanes JAK1. Itacitinib zeigt eine >20-fache SelektivitÄt fÜr JAK1 gegenÜber JAK2 und >100-fach gegenÜber JAK3 und TYK2; Itacitinib wird in der Erforschung der Myelofibrose eingesetzt.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1334298-90-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Itacitinib is a potent and selective inhibitor of JAK1, with >20-fold selectivity for JAK1 over JAK2 and >100-fold over JAK3 and TYK2; Itacitinib is used in the research of myelofibrosis.
Itacitinib (INCB039110) is a potent and selective inhibitor of JAK1, with >20-fold selectivity for JAK1 over JAK2 and >100-fold over JAK3 and TYK2. Itacitinib is used in the research of myelofibrosis[1].
References:
[1]. Mascarenhas JO, et al. Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. Haematologica. 2017 Feb;102(2):327-335.
Average Rating: 5 (Based on Reviews and 36 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *